Compare SXTC & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SXTC | BGB |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.7M | 525.7M |
| IPO Year | 2019 | N/A |
| Metric | SXTC | BGB |
|---|---|---|
| Price | $1.80 | $11.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.8K | ★ 154.6K |
| Earning Date | 08-19-2019 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,537,987.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $10.40 |
| 52 Week High | $7.84 | $11.97 |
| Indicator | SXTC | BGB |
|---|---|---|
| Relative Strength Index (RSI) | 65.99 | 52.04 |
| Support Level | $1.52 | $11.72 |
| Resistance Level | $1.61 | $11.89 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 80.49 | 75.00 |
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.